Nkgen Biotech Inc. reported its earnings for the first quarter (Q1) ended March 31, 2025. The company posted net income of USD 15.4 million for the period. Total other income (expense) amounted to USD 20.0 million. Research and development expenses were disclosed, but no significant variations were reported. There was no provision for income taxes for the quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001845459-26-000003), on January 20, 2026, and is solely responsible for the information contained therein.
Comments